Dosing is currently ongoing. DNL343, an eIF2B activator, is being evaluated in a phase II/III HEALEY study to treat amyotrophic lateral sclerosis (ALS). However, in January 2025, Denali announced ...

The South San Francisco biotech announced that eIF2B agonist DNL343 was unable to slow disease progression or increase survival compared to placebo at 24 weeks in the study, conducted at Sean M ...

The central nervous system candidate is eIF2B activator ABBV-CLS-7262, in a multiple dose study to assess its safety and pharmacokinetics in patients with amyotrophic lateral sclerosis ...

The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 ...

The development of resistance towards antibiotics poses a permanent threat in the fight against pathogenic microorganisms. Consequently, there is a constant need for new drugs to treat infectious ...

Adult-onset leukodystrophies and genetic leukoencephalopathies comprise a diverse group of neurodegenerative disorders of white matter with a wide age of onset and phenotypic spectrum. Patients with ...